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Recent advances in next-generation sequencing and other omics technologies capable
to map cell fate provide increasing evidence on the crucial role of intra-tumor
heterogeneity (ITH) for cancer progression. The different facets of ITH, from genomic
to microenvironmental heterogeneity and the hierarchical cellular architecture originating
from the cancer stem cell compartment, contribute to the range of tumor phenotypes.
Decoding these complex data resulting from the analysis of tumor tissue complexity
poses a challenge for developing novel therapeutic strategies that can counteract tumor
evolution and cellular plasticity. To achieve this aim, the development of in vitro and
in vivo cancer models that resemble the complexity of ITH is crucial in understanding the
interplay of cells and their (micro)environment and, consequently, in testing the efficacy of
new targeted treatments and novel strategies of tailoring combinations of treatments to
the individual composition of the tumor. This challenging approach may be an important
cornerstone in overcoming the development of pharmaco-resistances during multiple
lines of treatment. In this paper, we report the latest advances in patient-derived 3D
(PD3D) cell cultures and patient-derived tumor xenografts (PDX) as in vitro and in vivo
models that can retain the genetic and phenotypic heterogeneity of the tumor tissue.
Keywords: cancer models, PD3D cell culture, organoids, tumor heterogeneity, tumor microenvironment, tumor
evolution, cancer stem cells, PDX models
INTRODUCTION
Tumor subtyping across different patients is based on multiple cancer features, such as genomic
landscape, biomarker expression, and morphology, and it is routinely used in clinical settings.
These characteristics contribute to the definition of cancer phenotypes and ultimately to the
categorization of tumors in different stages and grades. At present, the design of targeted
therapies is mainly based on an understanding of the above described inter-tumor (inter-
patient) heterogeneity, although the presence of heterogeneity within an individual tumor is
broadly recognized. Increasing evidence suggests that intra-tumor heterogeneity (ITH) is clinically
relevant, as proven by the mutable “status” of molecular biomarkers in time and by the acquisition
of distinct phenotypes diverse from the primary tumor in metastatic lesions (Bedard et al., 2013).
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Russo et al. (2016) have recently shown that a biopsy from a
single lesion can be inadequate for the selection of a targeted
therapy directed at the treatment of multiple metastases within
the same patient. The multifaceted aspects of intra-tumor
heterogeneity include genetic and epigenetic heterogeneity as
well as phenotypic heterogeneity derived from the cellular
hierarchy originating from the cancer stem cell compartment
and microenvironment heterogeneity (De Sousa et al., 2013).
These components are strictly connected and interdependent,
participating in the temporal and spatial complexity and
mutability of tumor phenotypes. Independently from the
underlying mechanisms that lead to ITH, the fact that multiple
cell populations exist in the same tumor has strong clinical
implications. Patient-specific responses to therapy and the
development of resistance to chemo- and targeted therapies are
the direct results of ITH (Diaz et al., 2012).
Two main factors are responsible for ITH: (1) intrinsic
clonal dynamics in a cell’s genetic or epigenetic background
and (2) tumor-extrinsic factors in the non-cell autonomous
compartment. Cleary et al. (2014) have demonstrated that clonal
populations within the tumor exist dynamically in time and
space, competing with and eventually supporting one another,
and the entirety of this population defines the properties of
the tumor as a whole. Through the entire course of tumor
development and progression, malignant transformed cells
constantly undergo mutational events that in an evolutionary
fashion underlie a trial and error principle, which may or may
not result in a selective advantage relative to neighboring cells.
However, the selection process occurs at least in part as a response
to stressors, which may be stable or transient (Gupta et al.,
2011). Therefore, a gain of fitness in one clone relative to another
does not necessarily lead to the loss of the latter in favor of the
former. Extrinsically, the major factor contributing to ITH is
cellular interactions with the extracellular matrix (ECM), which
can alter gene expression, thus driving differentiation and altering
cell properties. It is possible that altered cell matrix contacts are
essential for the stability of clonal composition within a tumor
(Marusyk et al., 2012).
Not only the ECM but also the broader tumor
microenvironment with its cellular stromal components
influences ITH. Infiltrating cancer-associated fibroblasts (CAF)
are described as resistant to cytotoxic and targeted therapies
(Straussman et al., 2012), and only lately studies have shown
that these fibroblasts demonstrate a certain degree of plasticity
themselves (Augsten, 2014). The composition of the tumor
bulk in its variety of tumor cell clones and the infiltrating CAF
cause a broad range of responses toward systemic and targeted
treatment and can be in part responsible for the constant failure
of reliable predictions about treatment success. Therefore, in this
review, we first highlight the impact of ITH in clinical settings,
analyzing the consequences of ITH on patient management
and alternative therapeutic approaches potentially able to
overcome tumor evolution. Then, since tumor models able to
recapitulate different aspects of intra-tumor heterogeneity are
crucial in allowing researchers to decipher the dynamics of
cancer phenotypes and reshape therapeutic strategies, we shortly
introduce the different sources of ITH and subsequently focus
on the capability of patient-derived 3D (PD3D) cell cultures and





The emergence of sophisticated “omic” technologies has boosted
our understanding of the molecular events underlying cancer
development and progression. Despite these findings, the
development of new compounds often fails in the transition
from preclinical to clinical stages, which to a certain extent
is owed to preclinical models insufficiently recapitulating the
complexity of solid cancers. Data from the EMA and the FDA
suggest that new targeted drugs show an effect in 10–20% of a
non-stratified cohort, while proper stratification almost doubles
therapy efficiency. Huang et al. (2014) have published similar
numbers. As increasing tumor sequencing data becomes available
from large cohorts within the framework of multinational
sequencing projects such as the ICGC and the Cancer Genome
Atlas, researchers have identified more molecular subtypes of
tumors (Curtis et al., 2012; Guinney et al., 2015; Gaebler et al.,
2017). The use of cetuximab-based therapy in RAS wildtype
colorectal cancers (Khambata-Ford et al., 2007) and the use
of ALK kinase inhibitors in EML4-ALK-positive NSCLC (Shaw
et al., 2013) are two successful examples. Nevertheless, even with
appropriate companion diagnostics, such targeted therapies often
add only 6–12 months of progression-free survival until the
patient presents with disease progression (Huang et al., 2014). For
this reason, researchers and pharmaceutical groups have turned
to patient-derived organoids (Silvestri et al., 2017) or patient-
derived xenograft models (Hidalgo et al., 2014; Whittle et al.,
2015).
Tumors are highly adaptive to their (micro)environments.
Given this, understanding the mechanisms underlying tumor
development and clonal evolution will help researchers predict
their evolutionary trajectories, with direct implications for the
choice of therapeutic interventions. Since liquid biopsies entered
clinical routines, serial sampling of tumor genomes with minimal
intervention has helped researchers understand the evolution of
drug-resistance mechanisms over time (Haber and Velculescu,
2014) as well as the evolution of metastatic diseases (Carreira
et al., 2014). Also, analyses of micro vesicles and exosomes from
tumors found in patient serum have proven useful in allowing
researchers to predict the sites of future metastases for certain
tumor entities (Zarour et al., 2017). Any clonal event that drives
tumorigenesis may pose an attractive target model for drug
development. As such, the benchmark for successful clinical trials
in the approval process is progression-free survival in direct
comparison to the standard of care. Given the failure of targeted
therapies in advanced disease without prior chemotherapy, it is
likely that many targeted therapies have achieved this benefit for
patients by targeting early clonal events (e.g., driver mutations)
present in the majority of cells. Unfortunately, in the clinical
context, resistance to such therapies is frequently observed.
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Residual tumor cells remain viable after chemotherapy as a
result either of the selection of resistant clones present at low
frequencies in the treatment-naive tumor (Turke et al., 2010; Su
et al., 2012; Bhang et al., 2015) or of acquired mutations during
therapy (Hata et al., 2016).
Bozic and Nowak (2014) have estimated that upon diagnosis,
tumor lesions harbor at least ten or more sub-clones that
resist monotherapy. Consequently, single targeted agents are
unlikely to effectively kill all tumor cells. Targeted agents need
to be combined to collectively act through inhibition of distinct
pathways (Bozic et al., 2013). However, in practice, too little data
is available about the synergistic and toxic effects of combinatory
treatments and the biological consequences of the interplay
of the mutational landscape in the tumor, limiting the use of
such treatments in clinical settings. Therefore, the current focus
of preclinical, translational, and pharmaceutical research is to
exploit the immune system. Vaccine or adaptive T-cell therapy
approaches targeting multiple clonal neo-antigens minimize
normal tissue toxicity and maximize tumor cell kill while limiting
the possibility for acquired drug resistance. It remains to be seen
to what extent tumors are able to circumvent such strategies by
means of DNA repair defects, resulting genomic instabilities, and
thereby the loss of neo-antigens.
Genomic instability leads to cell-to-cell variation, fueling
selection, plasticity, and evolution. The clinical relevance of
genomic instability is reflected by the outcomes across multiple
cancer types and evidence linking chromosomal chaos with
metastasis (Turajlic and Swanton, 2016). Targeting mechanisms
underlying genomic instability may limit disease progression,
particularly in the early stages. One example of the successful
targeting of unstable cancers is the success of PARP inhibitors
in the treatment of BRCA mutant cancers. These inhibitors
increase genomic instability to lethal levels, resulting in synthetic
lethality (Lord and Ashworth, 2016). However, even with
this sophisticated therapeutic regimen, resistance can occur
either directly through additional mutations to BRCA or
indirectly through, for example, inactivation of 53BP1 (Lord
and Ashworth, 2016). Interestingly, Carey et al. (2017) have
recently demonstrated that the efficacy of PARP inhibitors in
MYC-driven triple-negative breast cancer cells can be further
increased by concomitant downregulation of MYC expression
using the cyclin-dependent kinase inhibitor dinaciclib. These
data highlight the importance of deeply characterizing the entire
tumor mass not only at tumor diagnosis but also during therapy
to detect any new occurring alterations that could pose potential
targets for adaptive therapies.
Evolutionary studies have revealed distinct mutagenic
processes that occur through the disease course, best studied
in the context of colorectal cancer (CRC) by Fearon and
Vogelstein (1990). However, evidence is also emerging in lung
adenocarcinoma, bladder cancer, estrogen receptor negative
breast cancer, head and neck squamous carcinoma, and
esophageal squamous carcinoma (Faltas et al., 2016; Law et al.,
2016). Progression-free survival (PFS) times as commonly
reported in clinical trials rarely translate to equivalent clinically
relevant overall survival benefits (Fojo et al., 2014). Preclinical
data from strictly stratified, well-characterized models does not
hold up with the variations and complexities of a clinical trial.
Progression-free survival frequently does not match overall
survival, and this evidence may reflect ITH effects. If, for
example, a dominant drug-sensitive clone is effectively targeted
in the investigational arm of a trial, this may allow resistant
sub-clones to undergo accelerated growth in a resource-rich
environment. Ultimately, this results in a more aggressive and
rapid disease progression compared to that in the control arm of
the trial.
To estimate the efficacy of new drugs, researchers must design
new trial concepts to allow for a more representative comparison
to current therapies. For this reason, Gatenby et al. (2009) have
designed study protocols in preclinical models that take into
account the influence of resistant sub-clones by maintaining
a stable population of sensitive clones (Enriquez-Navas et al.,
2016). In contrast to standard clinical practice, where the goal
of therapy is to maximally reduce tumor burden, the focus of
adaptive therapy is to maximize time to progression by stabilizing
tumor size (Gatenby et al., 2009; Enriquez-Navas et al., 2016).
Adaptive therapy is based on a two-phased strategy: (1) an
induction phase to avoid exponential tumor growth and (2) a
maintenance phase using progressively lower doses, potentially
including omitted schedules. In certain clinical settings, this
strategy could achieve better progression-free survival times
compared to standard fixed dosing. For example, in melanoma
PDXs, Stuart and colleagues demonstrated how vemurafenib-
resistant melanomas can acquire drug dependency such that an
intermittent rather than continuous dosing of the drug can delay
the onset of insuperable drug resistance (Das Thakur et al., 2013).
Traditional approaches to cancer management have primarily
focused on overcoming drug resistance through multiple lines
of treatment. In a more proactive approach, the tumor’s “next
move” would become predictable through an understanding
of evolutionary mechanisms and through the exploitation of
evolutionary constraints or synthetic lethality. In renal cell
carcinomas, Voss et al. (2014) examined five cases in which
patients had experienced a prolonged benefit from mTOR
pathway inhibition as a result of the use of everolimus or
temsirolimus. Multi-region tumor sampling, as first suggested
by Gerlinger et al. (2012), revealed parallel evolution of distinct
somatic mutations, leading to activation of the mTOR pathway
in independent areas of the tumor in three of the five cases
investigated (Voss et al., 2014). Although rather anecdotal, these
data suggest that targeting constraints to tumor evolution might
be practical if appropriate biomarker assays and preclinical
models are available. Collateral sensitivity, the phenomenon
through which acquired resistance to one drug comes at the
expense of sensitivity to another (Hill, 1986; Jensen et al.,
1997), is another example of how ITH can be exploited for
successful treatment by applying treatments aimed at reducing
karyotypic heterogeneity until a defined predictable state through
this initial drug exposure is reached. At this level, cells become
susceptible to a secondary drug. For example, Bardelli and
colleagues have demonstrated that KRAS mutant sub-clones of
colorectal cancers are more sensitive to withdrawal of an EGFR
monoclonal antibody-based regimen such as cetuximab than
are their wildtype counterparts. This suggests an evolutional
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disadvantage after the acquisition of KRAS mutations in later
tumor evolution, providing an explanation for further tumor
response in later treatment lines (Siravegna et al., 2015).
Zhao et al. (2016) have shown in murine models of
Philadelphia chromosome-positive ALL that collateral sensitivity
is induced by treatment with dasatinib, leading to acquired
resistance in the form of selection toward the BCR-ABL1 V299L
mutation during the evolution of Ph+ ALL cells. This in turn
generates cells sensitive to non-classical BCR-ABL inhibitors such
as cabozantinib and vandetanib.
Considering that the development of distant metastasis is the
main cause of death among cancer patients and that ITH strongly
influences tumor response to treatment, several groups have
focused their attention on profiling secondary tumor masses to
not only better understand tumor evolution but also define better
treatments for metastatic patients. Tumor metastases can in fact
be characterized by different molecular profiles compared to that
of the primary mass, and this heterogeneity might underlie the
limited therapeutic success in metastatic patients when treatment
is based only on the prognostic signature of the primary tumor.
In pancreatic cancer, Campbell et al. (2010) have shown that
amplification in cancer genes occurs predominantly in the early
steps of cancer development and that genomic instability persists
during cancer dissemination, with a consequent parallel and even
convergent evolution among different metastases. Moreover, this
study showed that metastasis-initiating cells are characterized
by genetic heterogeneity and that it is possible to define organ-
specific branches in the phylogenetic trees across metastases. This
specificity can be caused by the presence of particular genotypes
that drive metastatic cells to specific organs and/or by sub-clones
whose rearrangements make them more suitable for survival
in a specific secondary organ. Heterogeneity between primary
lesions and distant metastasis has been demonstrated not only in
pancreatic cancer but also in other tumor types, such as breast
cancer (Ng et al., 2017) and salivary adenoids cystic carcinoma
(Liu et al., 2017).
Heterogeneity between the primary tumor and distant
metastasis has been shown not only at the genomic level but
also considering protein activation (Silvestri et al., 2013).
In particular, a higher activation of the EGFR-PDGFR-cKIT
network, in addition to the PI3K/AKT pathway, has been
demonstrated in liver metastasis compared to primary colorectal
cancer tumors. Interestingly, recent work has shown that
when different metastatic masses from the same patient are
analyzed, heterogeneity among them is limited. In particular,
Makohon-Moore et al. (2017) have highlighted the presence
of identical mutations in well-known driver genes while the
ITH is related only to passenger gene mutations without
any functional consequences. The limited heterogeneity
characterizing secondary masses has been shown also by the
consistency between protein pathway activation profiling of
different regions of colorectal cancer liver metastases (Parasido
et al., 2017). Taken together, these data have important clinical
implications, highlighting the importance of secondary mass
profiling for therapy definition when the metastasis is the target
of the therapy. Moreover, if validated in clinical studies, recent
data highlighting limited heterogeneity in metastatic masses have
encouraging implications for the future success of therapies for
metastasis.
CELL CULTURE MODELS OF REGIONAL
GENOMIC ARCHITECTURE AND
INTRA-TUMOR HETEROGENEITY
Tumor evolution driven by genetic variations is surely the
most largely investigated source of inter- and intra-tumor
heterogeneity. The genetic component of intra-tumor
heterogeneity derives from selective pressure that allows
the growth of distinct clones. These clones interact with one
another within the same tumor. It is this interaction that
promotes or inhibits cell growth and often confers therapy
resistance in response to therapeutic interventions (Greaves and
Maley, 2012). Nowell (1976) introduced a model defining the
branching architecture of clonal evolution in cancer initiation
and propagation, describing this as a process through which the
mutation of a “progenitor normal cell” induces an advantage
in cell growth that determine the prevalence of the cancer
clone among the normal cell population in the tissue. Genomic
instability within this population can subsequently generate other
populations that, following Darwinian selection, occasionally
generate new leading sub-clones with a phenotypic advantage
(Nowell, 1976). Mutations leading clonal evolution are essentially
driven by system defects that maintain genome integrity (DNA
repair mechanisms), exposure to genotoxic agents, or treatment
with cytotoxic therapies. Thus, genomic instability results in the
accumulation of a high number of different genomic aberrations,
from single-point mutations to small insertions and deletions,
chromosomal rearrangement, or doubling of the entire genome
(Burrell et al., 2013). Random accumulation of these aberrations
results in a multitude of phenotypes controlled by the constant
selective pressure of the “healthy” tissue habitat. In this context,
the cancer microenvironment retains a tumor-suppressive role,
especially in cancer onset, but the reciprocal interaction of
the microenvironment and malignant cells contributes to this
dynamic modeling, which generates niches favorable to tumor
growth (De Palma et al., 2005; Lathia et al., 2011). In this view,
genetic differences between sub-clones of cancer cells, found
mostly between the primary and metastatic site, can be in part
explained by the different selection induced by the distinctive
microenvironments at both sites.
Increasing evidence shows that different cancer cell
populations resembling individual genetic clones within the
same tumor can evolve in parallel (allopatric speciation),
especially if physically separated within the tumor, or interact
through cooperative (symbiotic evolution) or competitive
(antagonist evolution) behavior (McGranahan and Swanton,
2015). Hobor et al. (2014) have observed an example of clonal
cooperation in colorectal cancer, where the growth of KRAS
wt sub-clones, usually sensitive to cetuximab, are supported by
KRAS mutant sub-clones. Marusyk et al. (2014) have likewise
observed that tumor growth can be supported by sub-clones
that do not necessarily have enhanced fitness but can impair
microenvironment integrity and consequentially improve the
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non-cell autonomous growth of polyclonal tumors. In addition,
the authors have demonstrated that the interaction of different
sub-clones, overexpressing secreting factors, can develop new
phenotypic traits, such as metastatic and hemorrhage features.
As regards multiregional sampling and analyses, the exome
sequencing of samples obtained through a spatially separated
biopsy of primary renal carcinomas and metastasis shows a high
percentage of somatic mutation not detectable in different areas
of the same tumor. Intra-tumor heterogeneity shows on one hand
the presence of different phenotypes within the tumor (mTOR
mutation) or, on the other, heterogeneous mutation sites in the
same genes (SETD2, KDM5 and PTEN), indicating a phenotype
convergence in the evolution of the tumor (Gerlinger et al., 2012).
Moreover, multiregional sequencing shows that in clear cell renal
carcinoma, intra-tumor driver genomic aberrations are delimited
to spatially separated sub-clones, and their numbers increase
with the number of samples analyzed without saturation,
suggesting that the analysis of a single biopsy can largely
underestimate the prevalence of driver mutations in a patient
(Gerlinger et al., 2014).
Recently, it has been shown that next-generation sequencing
combined with the establishment of patient-derived primary cell
culture can improve the analysis of intra-tumor heterogeneity
and help to overcome its consequences on the development of
drug-resistant sub-clones. In this framework, Gao et al. (2017)
studied intra-tumor heterogeneity in hepatocellular carcinoma
(HCC), sequencing primary cancer cell cultures derived from
different regions of tumors from 10 patients (for a total of
55 regions). Evidence of heterogeneous mutations (39.7%) and
branched evolution were found in each tumor, and in the
presence of targetable genomic aberrations, the sensitivity of
the cell culture to the specific drugs was confirmed. Moreover,
high throughput screening was performed to identify drugs able
to affect the viability of resistant sub-clones. Interestingly, the
authors demonstrated that cell cultures retained a mutational
profile highly similar to the original tissue also at high passages,
supporting the use of a long-term primary cancer cell culture
as an in vitro model to assay the effect of intra-tumor
heterogeneity on drug sensitivity. Gerber et al. (2017) have
similarly investigated inter- and intra-tumor heterogeneity in
primary cell cultures derived from three melanoma metastases
from three different patients (BRAF wt/NRAS wt, BRAF
mut/NRAS wt, and BRAF wt/NRAS mut). The authors analyzed
inter- and intra-tumor heterogeneity by means of single cell
RNA-seq, identifying CDK4, highly expressed in most of the
sub-clones derived from BRAF wt/NRAS wt tumors, as a
potential therapeutic target. Moreover, a small population of cells
expressing the ABC transporter ABCB5, the stem cell markers
CD271 and CD133, and aldehyde dehydrogenases (ALDH) was
identified within the same tumor.
Few studies have investigated the ability of patient-derived 3D
(PD3D) cell cultures to retain genetic intra-tumor heterogeneity.
Weeber et al. (2015) have shown that 3D cell cultures (organoids)
can be successfully generated from biopsies of colorectal cancer
metastases and that these organoids retain 90% of somatic
aberrations when compared with the original cancer tissues. The
presence of discrepancies in 15 mutations have been attributed
to intra-tumor heterogeneity. Giessler et al. (2017) have also
investigated genetic sub-clone composition in colorectal cancer
by means of whole genome sequencing of three patient tumors
and the corresponding (short- and long-term) 3D cell cultures
(spheroids) and xenografts. Analyzing small nucleotide variants
and copy number alterations, the authors identified at least two
genomic sub-clones coexisting in each primary tumor and at least
three sub-clones in patient-derived spheroids and xenografts.
Interestingly, these sub-clones were dynamic in both spheroids
and xenografts, suggesting that different dominant sub-clones
drive cell growth in these two models.
Van de Wetering et al. (2015) have generated a library of
22 patient-derived colorectal cancer organoids and compared
the genomic landscape of these and the corresponding tissue
biopsies, demonstrating that the polyclonal architecture of
tumor biopsies is essentially maintained in vitro. Interestingly,
a comparison of biopsies derived from two patients with two
tumors each showed in one case the same alteration in TP53
R273C and BRAF V600E, indicating the derivation from a
common progenitor and the subsequent divergence of sub-
clones, while the biopsies obtained from the other patient showed
different driving mutations in APC and P53. In both cases,
the corresponding organoid cultures recapitulated the genomic
landscape observed in the biopsies. Recently, Bruna et al. (2016)
have also shown that patient-derived xenografts from breast
cancer tissue and xenograft-derived cell cultures are able to
preserve the intra-tumor genomic architecture of the original
tumor tissue. In this study, the authors performed a drug
screening using an ex vivo model consisting of both single cells
and small tissue-derived cell aggregates (<40 µm). The effect
of several drugs identified in vitro were also validated in vivo,
demonstrating the reliability of this cell culture platform for
pharmacogenomic studies.
The crucial role of a sub-population of cancer cells with
stem-like properties has been largely investigated in the onset,
growth, and propagation of glioblastoma (Galli et al., 2004;
Lathia et al., 2015). These cells can be isolated from patient
tissue as primary 3D neuro-spheres, propagated in vitro, and
engrafted in immunodeficient mice. Using cytogenetic analysis
and whole exome sequencing, Piccirillo et al. (2009) have shown
that populations of glioblastoma cells with different genomic
aberrations coexist within different regions of the same tumor,
supporting the culture of glioblastoma neuro-spheres as a potent
tool for the study of genetic intra-tumor heterogeneity and the
evaluation of drug responses in vitro and in vivo.
The model proposed in Figure 1 recapitulates a potential
workflow (“Reverse Clinical Engineering”) applicable for the
development of a precision medicine platform, integrating
multiregional sampling, molecular characterization, and PD3D
cell culture drug testing to improve the design of targeted
therapy and overcoming at least in part the consequences of
intra-tumor heterogeneity in clinical scenarios. The feasibility
of this approach has been previously proposed by Pauli et al.
(2017), who have tested for drug resistance in PD3D and PDX
models, integrating data derived from sequencing and histology
of tumor tissues. In our opinion, the use of multisampling in
space (biopsies from different tumor regions) or in time (serial
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FIGURE 1 | Potential applications of PD3D cell cultures derived from multiregional cancer biopsies in therapy selection (“Reverse Clinical Engineering”). The
illustration shows how 3D cell cultures derived from multiregional sampling or biopsies can potentially improve the design of targeted therapies in cancer patients.
biopsies in different time frames of tumor evolution) could
improve the design of combined targeted therapies, overcoming
ITH-derived drug resistances. Moreover, considering the need
for less invasive diagnostic procedures, the use of liquid biopsies
aimed at allowing the collection of circulating tumor DNA
(ctDNA) (Russo et al., 2016) or circulating tumor cells (CTCs)
could be a valid alternative, allowing researchers to follow tumor
evolution in time and space, assuming the ctDNA and CTCs
could represent multiple lesions.
CANCER STEM CELL COMPARTMENTS
AND HIERARCHICAL CELLULAR
HETEROGENEITY IN PD3D CANCER
CELL CULTURE MODELS
As previously described in the introduction paragraph, genetic,
epigenetic, and phenotypic features contribute dynamically to
the establishment of intra-tumor heterogeneity. For a long time,
the clonal evolution model and the cancer stem cell model
have competed in their explanations of the origins of tumor
heterogeneity, but Kreso and Dick (2014) have recently shown
that these two theories are highly complementary more than
mutually exclusive. Within numerous malignant tissues, it has
been shown that a small population of cells is responsible
for the initiation, survival, and growth of the tumor. This
population of cells, termed either cancer stem cells (CSCs) or
tumor-initiating cells (TICs), has stem cell–like features and is
responsible for the hierarchical organization of cells within the
tumor, as is the normal stem cell counterpart in healthy tissue
(Kreso and Dick, 2014). CSCs have a self-renewal capability
(asymmetric division) and the ability to generate a progeny
of cells that can undergo differentiation, thus generating the
hierarchy observed in some cancer tissues (Batlle and Clevers,
2017). CSCs were initially identified in acute myeloid leukemia
(AML) as a CD34+ CD38− subpopulation capable of initiating
leukemia after engraftment in immunodeficient mice (Lapidot
et al., 1994). Subsequently, numerous studies in solid tumors
have identified markers to define subpopulations of cancer
cells able to initiate cancer and maintain the hierarchical
organization in xenograft assays (Medema, 2013). CSC markers
include CD44+/CD24−/low in breast cancer (Al-Hajj et al.,
2003), CD133+ in brain tumors (Singh et al., 2004) and CRC
(Ricci-Vitiani et al., 2007), ALDH high in thyroid cancer
(Todaro et al., 2010), CD44+/α2β1high/CD133+ in prostate
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cancer, and numerous markers in other solid tumors (Medema,
2013).
Cellular hierarchy can vary among different tumor entities:
It can be organized in highly defined differentiation steps
(steep hierarchy) or in a similar ratio between stem cells
and differentiated non-tumorigenic cells (shallow hierarchy)
(Meacham and Morrison, 2013). However, Roesch et al. (2010)
have demonstrated that melanoma growth does not follow
the typical hierarchical model; rather, the population of cells
responsible for tumor heterogeneity is highly dynamic in time.
In CRC, Francescangeli et al. (2015) have shown that Cripto-1
can dynamically regulate the cancer stem cell compartment
in vivo and in vitro through Src/Akt signaling, suggesting that
cancer cells can change their status from non-tumorigenic to
tumorigenic and vice versa, occupying different places of the
stemness hierarchy tree in different time frames. The ability of
CSCs and more differentiated cells to dynamically change their
phenotype is a prerogative of CSC plasticity. This mechanism is
also involved in cancer onset; thus, Schwitalla et al. (2013) have
demonstrated that differentiated intestinal epithelial cells within
an inflammatory context undergo a dedifferentiation process
led by Wnt that drives the acquisition of self-renewal stem-like
features. Recently, Shimokawa et al. (2017) have studied CSC
hierarchy and plasticity in human CRC-derived PD3D models by
tracking in vitro and in vivo the expression of fluorescent markers
located in the LGR5 (stem cells) or KRT20 (differentiated cells)
locus. The authors showed that although the selective elimination
of LGR5+ initially reduced tumor growth, the LGR5+ population
subsequently reappeared, as demonstrated by the regrowth of
the tumor. The authors suggest that differentiated CRC cells
expressing KRT20 are able to generate LGR5+ cells only if the
CSC niche is not occupied by the original LGR5+ cells.
Increasing evidence suggests that the CSC model principally
contributes to intra-tumor heterogeneity by introducing
functional diversity due to the coexistence of cells at different
levels of the hierarchical tree within the bulk of tumor cells.
Beyond the genetic alteration contributing to the clonal
evolution of the tumor, described in the previous paragraph,
the cancer epigenome has been shown to contribute to the
establishment of different cellular phenotypes, representing the
CSC-based hierarchical organization of the tumor (Easwaran
et al., 2014). Both genetic and epigenetic alterations are strictly
interconnected, since in different tumor entities it has been
shown that mutation in genes coding for proteins involved in
chromatin organization and DNA methylation are frequently
represented (Shen and Laird, 2013). Moreover, the promoters
of a high number of genes differentially regulated in cancer
are known to be linked to chromatin, highly regulated in
embryonic or adult stem cells. This chromatin, also called
bivalent, is characterized by the presence of both repressive and
active histone marks (respectively, H3K27me3 and H3K4me3)
within not-methylated GpC island promoters and can switch
between active or passive transcriptional activities during
differentiation. The promoters of genes with bivalent chromatin,
normally involved in embryonic development, are frequently
hyper-methylated in cancer, altering the self-renewal feature
of tumor cells, interfering with their differentiation, and
contributing to the establishment of the CSC phenotype
(Easwaran et al., 2012).
Torres et al. (2016) have demonstrated that in different
tumors, the expression of the histone H1.0 is highly
heterogeneous, and its epigenetically regulated silencing
correlates with the self-renewal feature and tumorigenic ability,
suggesting the rescue of H1.0 expression as a potential CSC
targeted therapy. Recently, multiregional sampling of human
glioblastoma followed by a transcriptomic profile by Jin et al.
(2017) has shown that the perivascular and hypoxic tumor
regions have two distinct gene expression programs associated
with heterogeneity in the composition of glioblastoma stem cells
(GSCs) derived from these two niches. Moreover, the authors
have identified two chromatin modeling proteins, part of the
polycomb-repressing complexes EZH2 and BMI1, as crucial
players in the tumorigenic potential of the two different pools of
GSCs. Finally, in this study, a therapy based on the combined
inhibition of EZH2 and BMI1 was able to overcome the drug
resistance caused by GSC heterogeneity.
Increasing evidence of the crucial role of CSC in tumor
progression highlights the urgent need for sophisticated in vitro
cancer models recapitulating the hierarchical structure observed
in patient tissue to identify new efficient therapeutic approaches.
In fact, Vermeulen et al. (2012) have demonstrated that the
presence of CSC subpopulations is in part responsible for therapy
resistance and cancer recurrence. In numerous tumor entities,
treatment with cytotoxic drugs has been shown to enrich the CSC
subpopulation, supporting the need to develop in vitro models
capable of retaining cancer stem cells to test drug efficacy. It
has been largely demonstrated that patient-derived 3D (PD3D)
cell cultures (organoids or spheroids) are hierarchically organized
cellular models suitable for the investigation of the impact of
new therapies on cancer growth. For example, it has been shown
that PD3D cell cultures obtained from colorectal cancer comprise
self-renewing forming cells, low proliferating cells, and post-
mitotic cells and that the percentage of these classes of cells is
relatively stable in serial re-plating experiments, demonstrating
that PD3D cell cultures maintain a linear functional cell hierarchy
and that only a subclass of tumor-initiating cells (TICs) drives
tumor onset, growth, and metastatic formation (Dieter et al.,
2011). More recently, Giessler et al. (2017) have investigated
the origin of this functional heterogeneity by analyzing primary
CRC tumors, tumor-derived xenografts, and PD3D cell cultures
by means of whole genome sequencing and functional assays.
They showed that different genomic sub-clones were found in
the original tumor and in both xenograft and PD3D cultures,
demonstrating that TcICs (tumor clone-initiating cells) were
genetically heterogeneous, contributing differently to tumor
growth.
Recently, Fujii et al. (2016) have generated a library of
organoids derived from 52 tumors with different subtypes and
grades of colorectal cancer. Isolated organoids recapitulated the
histotypes of the patients’ tumors, and a reduction in number
of niche factors was observed in the transition from adenoma
to carcinoma. Moreover, heterogeneity in gene expression
within tumor organoids deriving from a single patient and
between organoids deriving from different CRC patients has
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been analyzed by means of single organoid RNA-sequencing,
showing that heterogeneity is present in both comparisons
(van de Wetering et al., 2015). Finally, CRISPR/Cas9-based
genome editing allows the tracing of human CRC PD3D models
expressing EGFP under the control of an LGR5 promoter to
follow the fate of CSCs in vitro and in vivo. These experiments
have confirmed the hierarchical organization of CRC, showing
the ability of CSCs to maintain their self-renewal properties as
well as their capability to differentiate (Cortina et al., 2017).
As previously described, Singh et al. (2003, 2004)
have been able to generate PD3D cell cultures (tumor
spheres) from different pathological subtypes of brain
tumors (medulloblastoma, astrocytoma, ganglioglioma, and
ependymoma). PD3D cell cultures derived from these tumor
entities retained self-renewal, proliferation, and differentiation
capabilities, confirming their stem cell identity. Interestingly,
isolated PD3D cell cultures were positive for stem cell
markers such as CD133+ and nestin, but only when plated
in differentiation media were they able to express neural
differentiation markers. Moreover, the authors demonstrated
that only the CD133+ subpopulation maintains its self-renewal
capacity in vitro, and it is able to generate tumors in immuno-
deficient mice that recapitulate the phenotypes of patient
tumors. Recently, Hubert et al. (2016) have developed a novel
3D organoid culture system to recapitulate glioblastoma cancer
stem cell heterogeneity. The authors showed that patient-derived
cancer cells can be grown for months without passaging,
generating organoids of variable size (in the range of millimeters)
that contain a cancer stem cell compartment comparable with
the culture of canonical glioblastoma-derived tumor spheres.
Interestingly, organoids derived from multiple regions of
the same astrocytoma can engraft with different efficiency in
immunodeficient mice, reflecting the functionally different
subpopulations present in different regions of the same tumor.
In breast cancer, Pece et al. (2010) have demonstrated that the
signature of human normal mammary stem cells is able to stratify
breast cancers (basal tumors from the other subtypes) and that
CD49F+/DLL1H/DNERH cells but not DNERL, both from poorly
and well-differentiated tumors, are enriched in stem cells, as they
can generate PD3D cell cultures and tumors in immunodeficient
mice. Moreover, Tosoni et al. (2015) have recently shown that
Numb is crucial for the maintenance of human mammary
stem cell identity in the process of asymmetric cell division
and progenitor maturation, and the loss of this gene induces
EMT, resulting in the reacquisition of stemness characteristics.
Recently, Tosoni et al. (2017), using breast cancer PD3D cell
culture models and PDX, have demonstrated the efficiency of the
inhibitor Nutlin-3, alone and in combination with chemotherapy,
in inhibiting Numb− tumor growth, metastasis, and tumor
relapse in vivo, suggesting this inhibitor as an effective drug to
selectively target CSC.
Huang et al. (2015) have generated 3D cultures from primary
human pancreatic adenocarcinoma. These organoids recapitulate
the histology architecture, express the same differentiation
markers, and maintain the phenotypic heterogeneity of patient
tumors. Moreover, they generate tumors when engrafted in
immunodeficient mice, showing also a retention of the stem cell
compartment. Recently, to study the role of the epigenome in
the maintenance of the stem cell compartment of pancreatic
ductal adenocarcinoma, Zagorac et al. (2016) have analyzed
the DNA methylome in pancreatic CSCs. Using pancreatic
cancer PD3D models, the authors demonstrated that the DNA
methyltransferase is crucial to the maintenance of the self-
renewal feature among CSCs, suggesting that the targeting of
epigenetic regulators could improve therapy efficacy in pancreatic
cancer patients.
IN VITRO 3D MODELS SIMULATING
TUMOR MICROENVIRONMENT
HETEROGENEITY FOR THE STUDY OF
TUMOR PROGRESSION AND
SENSITIVITY TO TREATMENT
Tumor development and metastatic progression are not isolated
processes simply driven by survival and proliferation of
altered epithelial cells; rather, they are complex mechanisms
characterized by the dynamic interaction of neoplastic cells
with components of the surrounding microenvironment, such
as soluble factors, fibroblasts, tumor vasculature, and immune
cells (Figure 2) (Mueller and Fusenig, 2004; Tlsty and Coussens,
2006; Hu and Polyak, 2008). Under healthy conditions,
the microenvironment represents a barrier against tumor
development (Dolberg and Bissell, 1984; Barsky and Karlin,
2005; Polyak and Hu, 2005). The presence of abnormal cells
induces critical changes in the mechanical properties of the ECM
(DuFort et al., 2011) as well as in the secretion of chemokines,
cytokines, growth factors, and matrix remodeling factors (Allinen
et al., 2004), which in turn activate a process of tumor–
microenvironment co-evolution that sustains tumorigenesis (van
den Hooff, 1988; Ronnov-Jessen et al., 1996).
Recently, Thery et al. (2002) have identified a mechanism
of inter-cellular communication based on the secretion of
extracellular vesicles involved in pre-metastatic niche formation.
All cell lineages in the tissues as well as cancer cells can secrete
into the extracellular compartment small vesicles (30–150 nm)
called exosomes that carry a variety of molecules such as lipids,
proteins, RNA, and DNA. Through this mechanism, cancer cells
can modify the local microenvironment as well as systematically
alter distant organ tissues, supporting the formation of the pre-
metastatic niche (Azmi et al., 2013; Lobb et al., 2017). Since
exosome content is strictly related to the cell of origin, exosomes
represent an interesting tool for the identification of novel
diagnostic and prognostic biomarkers (Xu et al., 2016).
The fundamental role of the cross-talk between tumor
epithelial cells and the surrounding microenvironment was
observed more than a century ago, when the seed and soil
hypothesis was proposed (Paget, 1989). In particular, this model
postulated that tumor preference for metastasis in specific
secondary organs was due to both the intrinsic characteristics of
specific cancer cells and a favorable interaction between tumor
cells (the “seed”) and the organ microenvironment (the “soil”).
Moreover, it has been demonstrated that tumor cells in the
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FIGURE 2 | In vitro co-culture models of tumor–microenvironment interaction. The cartoon shows the main in vitro 2D and 3D co-culture models used to study
tumor–microenvironment crosstalk.
primary site can directly activate hematopoietic progenitors that
migrate from the bone marrow to the future metastatic site,
creating a suitable milieu for metastatic spreading (Kaplan et al.,
2005, 2006).
A fundamental step for tumor progression is the
dissemination of malignant cells to distant organs through
blood circulation. It has been shown that CTCs are present
in the blood stream of tumor patients already at early stages,
when the presence of distant metastasis is still not clinically
detectable (Braun et al., 2005; Sanger et al., 2011). Since
CTCs can be easily collected with low invasive methods and
represent specific tumor sub-clones with the ability to migrate
and survive in the blood stream and to eventually reach and
colonize secondary organs, their importance as prognostic and
predictive biomarkers is clear (Mocellin et al., 2006; Rahbari
et al., 2010; Miyamoto et al., 2012; Zhang et al., 2012), as is
their promise in the study of both spatial and temporal tumor
heterogeneity (Babayan et al., 2013; Heitzer et al., 2013; Mostert
et al., 2013). Due to the high potential of CTCs not only for use
in biomarker characterization but also as experimental models
for the study of tumor progression and treatment susceptibility,
several research groups have developed new methods for
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in vitro culturing of CTCs (Khoo et al., 2015; Vishnoi et al.,
2015). Zhang et al. (2013) isolated CTCs from breast cancer
patients and developed long-term in vitro cell lines based on a
two-step cultivation method from 3 out of 38 patient samples.
The molecular characterization of the cell lines highlighted a
potential signature of brain metastasis based on the expression of
the four markers HER2+/EGFR+/HPSE+/Notch1+. Moreover,
the authors demonstrated the ability of CTCs expressing these
markers to metastasize to the lung and brain after injection in
immunodeficient mice.
In a proof-of-concept study, Yu et al. (2014) demonstrated
the feasibility of using CTC-derived cell lines when selecting the
best therapeutic options for individual cancer patients. In this
study, the authors showed that non-adherent and hypoxic (4%
CO2) culture conditions strongly improved in vivo proliferation
abilities of CTCs isolated from estrogen receptor positive breast
cancer samples. Interestingly, only CTCs isolated from recurrent
patients formed long-term in vitro cell lines, suggesting a
correlation between tumor susceptibility to treatment and CTC
status. Finally, a different sensitivity to drugs targeting ER,
PI3KCA, and HSP90 was shown, demonstrating the potential
of using CTC-derived cell lines when defining new therapeutic
targets for individual tumors. The ability of CTCs from patients
with breast cancer to grow as 3D spheroids has been also
demonstrated by Vishnoi et al. (2015), who isolated the CTC
fraction positive for the stem cell signatures of CD44+/CD24−.
The potential of using CTC-derived in vitro cell lines as
experimental models has been proven not only in breast cancer
but also in other tumor types, such as prostate cancer (Gao et al.,
2014), colon cancer (Cayrefourcq et al., 2015; Grillet et al., 2017),
and gastric cancer (Kolostova et al., 2016).
Considering the fundamental role tumor microenvironment
plays in cancer development as well as in chemo-resistance, new
therapeutic approaches have been developed to target not only
tumor cells but also components of this supporting environment
(Loeﬄer et al., 2006; Rossler et al., 2008; Dougan and Dranoff,
2009). Due to the heterogeneous composition of tumor tissues,
more complex preclinical models are needed to better simulate
human tumor biology. In this context, in vitro models, even
as simplified representations of the complex cancer biology, are
flexible tools that allow study of the crosstalk between different
tumor components under controlled experimental conditions.
To this aim, several co-culture models with different levels
of complexity have been developed. The simple use of a
conditioned medium (Figure 2) allows analysis of the effect of
soluble factors on cell behavior, while migratory and invasive
abilities can specifically be studied using transwell systems with
different cell types plated in separate compartments (Figure 2)
(Boyden, 1962). These two approaches are simple and easy
to handle, but they do not allow study of cell–cell and cell–
microenvironment interactions. To better understand the role of
direct crosstalk between cells in cancer development and chemo-
resistance, several co-culture systems have been developed where
different cell types are simultaneously grown in direct contact
with one another (Figure 2). To study the effect of tumor
microenvironment on treatment resistance, Straussman et al.
(2012) have analyzed the ability of stroma cells to affect the drug
sensitivity of cancer cells, demonstrating that the efficacy of anti-
cancer drugs in inducing cell death was reduced in the presence
of stromal cells. Moreover, this effect was more pronounced
when, in comparison to chemotherapy, target agents were used,
highlighting the importance of the tumor microenvironment in
influencing intracellular molecular pathways.
Even if direct co-culture models better represent the complex
nature of tumor tissue, one of the main limitations is represented
by the fact that these were initially based on 2-dimensional
cultures, which do not mimic the three-dimensionality of a
tumor in vivo. The recent development of more complex three-
dimensional (3D) co-culture methods has allowed researchers
to study tumor biology in a system that more closely resembles
the physiological situation. Cancer-associated fibroblasts (CAFs)
are altered fibroblasts actively involved in tumor development
and progression, and a correlation between their abundance and
poor prognosis has been demonstrated in several cancer types
(Fujita et al., 2010; Yamashita et al., 2012). Considering their
fundamental role in tumor progression (Bhowmick et al., 2004;
Kalluri and Zeisberg, 2006), several tumor epithelium-fibroblast
co-culture models have been developed. Li and Lu (2011) co-
cultured 4T1 cells with murine embryonic fibroblasts (MEF) in
a 3D system. To optimize spheroid formation, different protocols
were compared, demonstrating the critical effect of the presence
of a basement membrane in the form of Matrigel not only
in the pre-coated wells but also in the culture medium. The
incorporation of fibroblasts led to the formation of “polarized-
like” alveolar and ductal structures similar to those observed
in vivo, the morphology of which was influenced by the amount
of fibroblasts present, with ductal networks developed only
with a higher percentage of MEFs (above 50%). Other groups
have likewise studied the effect of co-cultures on breast cancer
progression (Jaganathan et al., 2014). Rama-Esendagli et al.
(2014) used a three-component system comprising 4T1 breast
cancer cells, NIH/3T3 and 3T3-L1 fibroblasts, and J774A.1
macrophages to show that breast cancer cell spreading and
invasion were primarily supported by fibroblasts, while the
presence of both fibroblasts and macrophages increased the
capacity for 3D growth.
Another component of the surrounding microenvironment
that strongly influences tumor cell survival and sensitivity
to treatment as well as the ability to metastasize is the
vascular network. Formation of new vessels and modification
of the existing vascular network within a tumor are well-
known processes allowing tumor cells to adapt to a constantly
transforming environment (Chang et al., 2000; Hillen and
Griffioen, 2007). The variability in this network, which supports
the delivery not only of nutrients and oxygen but also of
drugs to tumor cells, can therefore contribute to phenotypic
heterogeneity, such as different tumor cell proliferation areas
inside the tumor mass and differential responses to therapy
(Tong et al., 2004; Multhoff and Vaupel, 2012; Fan et al., 2013).
Chwalek et al. (2014) have successfully used in situ–forming
starPEG-heparin hydrogels containing covalently bound integrin
ligands and reversibly conjugated pro-angiogenic growth factors
to develop a well-organized endothelial capillary network. The
authors demonstrated the feasibility of applying this system
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for the study of heterotypic cell–cell interactions during tumor
vascularization by transferring pre-formed hepatocarcinoma
cell spheroids into hydrogels containing endothelial cells and
analyzing the ability of these cells to migrate inside the tumor
spheroids.
Recently, the effect of tumor microenvironment manipulation
on cancer progression was analyzed using a complex 3D
model where HT29 and HCT116 colorectal adenocarcinoma
cells were co-cultured with human dermal fibroblasts (HDFs)
and human umbilical vein endothelial cells (HUVECs). In this
work, Magdeldin et al. (2017) demonstrated that ECM density
strongly influenced cell migration patterns and that laminin, one
of the components of the basement membrane, was involved
in the regulation of endothelial cell morphology and vascular
network formation. Moreover, they showed the simultaneous
presence of glandular structures, polarized collective migration,
and elongated cells during tumor cell migration, suggesting
the involvement of several distinct mechanisms in this process.
Interestingly, 3D tumor spheroids with a size bigger than 500 µm
mimic themselves the typical layer-like structure observed in a
tumor mass with an inner necrotic core due to the presence of
hypoxic areas, surrounded by a middle quiescent part and an
outer layer of proliferating cells (Mueller-Klieser, 1984; Carlsson
and Acker, 1988; Alvarez-Perez et al., 2005).
The immune system plays a fundamental role in preventing
tumor development and progression by recognizing and
eliminating aberrant cells. However, under constant immune
pressure, neoplastic cells can evade immune surveillance and
instead co-opt immune cells to favor their sustained proliferation
(Kim et al., 2007). Pioneering work by Sutherland et al. (1977)
demonstrated that allo-specific spleen cells were able to infiltrate
tumor spheroids and kill cancer cells. Since then, several research
groups have focused on the development of new therapeutic
approaches that take advantage of the cytotoxic effect of the
immune system. In this context, several co-culture models of
tumor cells with components of the immune system have been
developed. By co-culturing HT29 cells with THP1 macrophages
in the presence of immunostimulants such as heteroglycans or
LPS, Devi et al. (2015) have demonstrated the efficacy of activated
macrophages in killing tumor cells. The cytotoxicity not only of
macrophages but also of other immune cells such as NK cells
(Giannattasio et al., 2015) monocytes (Konur et al., 1996, 1998),
and leukocytes (Hirschhaeuser et al., 2009) has also been studied.
In the study of tumor progression as well as response to
treatment, selection of the most appropriate model is essential
since the composition of the in vitro system can strongly
influence the result of the analysis. Recently, Lal-Nag et al.
(2017) compared the effects of different experimental models on
ovarian cancer drug sensitivity. In particular, they developed a
3D model comprising ovarian cancer cells alone or co-cultured
with the omentum metastatic niche, and they demonstrated
that different microenvironments strongly influence response
to treatment. Since development of distant metastasis is the
main cause of death among cancer patients, experimental models
that mimic the metastatic process are strongly needed to allow
for the study of crosstalk between tumor cells and the tumor
microenvironment. Recently, Holen et al. (2015) developed a
humanized bone model to study breast cancer metastasis. In
particular, they used trabecular bone cores obtained from the
femoral heads of patients undergoing hip replacement surgery
to seed the human breast cancer cell lines MDA-MB-231 and
T47D. The use of bone disks allows for the maintenance of all
cell types present in the bone and involved in breast cancer
colonization, making these disks a perfect model for the study
of breast cancer bone colonization and metastatic development.
A similar approach has been used to culture breast and prostate
cancer cells, isolating bone tissues from female and male patients,
respectively (Salamanna et al., 2016).
Among bone marrow components, adipocytes play a critical
role in bone metastatic progression. To study the interaction
between tumor cells and adipocytes, Herroon et al. (2016) have
developed a transwell-based in vitro model co-culturing prostate
tumor cell spheroids in the presence of bone marrow–derived
adipocytes. The constant exposure to soluble factors produced by
adipocytes allows for the analysis of their influence on prostate
cancer cell behavior. Moreover, the authors directly co-cultured
the two cell types to study the mechanism of tumor cell invasion
toward the adipocytes. Adipocytes and tumor cells were separated
by a layer of collagen I, and a time course analysis allowed for
definition of the ability of cells to invade the collagen matrix and
for examination of how this is influenced by adipocytes.
Hoffmann et al. (2015) have studied the sensitivity of different
colorectal cancer models to clinically relevant combination
therapies and to targeted therapeutics. In particular, they
compared the drug response of colorectal cancer cell line
grown as spheroids comprising tumor cells alone or tumor cells
co-cultured with peripheral blood mononuclear cells (PBMCs)
or with primary cancer-associated fibroblasts to the response
of spheroids directly isolated from colon cancer tissues. After
treatment, an alteration in cell response was observed when
diverse tumor microenvironments were used. Moreover, distinct
response patterns not detectable in the cell line–based models
were revealed in the patient-derived spheroids. Taken together,
these data demonstrate the complexity of the influence of tumor
microenvironment on drug sensitivity. Even considering the
difficulty of obtaining fresh tumor tissue and the intrinsic patient
to patient variability in drug response, cancer spheroids directly
isolated from fresh tumor tissues with preservation of cellular





It has been demonstrated that PDXs preserve the morphology
and 3D architecture found in original human tumor tissue.
Nevertheless, the interaction of human cells with the murine
microenvironment could alter cell features and behavior as
a result of interspecies (in)compatibility. In the history of
preclinical models, patient-derived xenografts pose a significant
advantage over classical cell line models (Hidalgo et al.,
2014; Aparicio et al., 2015; Byrne et al., 2017). PDX models
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autonomously recapitulate much of the inter- and intra-tumor
heterogeneity of the donor tumor tissue (Nguyen et al., 2014;
Eirew et al., 2015), which make them the gold standard for
oncologic drug discovery and preclinical development. At the
same time, they can be used to study resistance to chemotherapy
through the use of isogenic cellular clones, as shown in colorectal
PDX models (Kreso et al., 2013).
As explained above, clonal populations within the tumor exist
dynamically in time and space. Three main approaches are used
to describe clonal dynamics. Phenotypic clones are investigated
by lentiviral barcoding, mutational clustering by following
genomic clones, and single cell–based by computational
approaches (Fisher et al., 2013; Eirew et al., 2015). For example,
Ding et al. (2010) have found that PDX models established from
a basal-like breast cancer are more representative of a patient’s
metastatic lesion than of the primary tumor. Using a Bayesian
clustering method for grouping somatic mutations, Eirew et al.
(2015) have likewise reconstructed the genomic clonal dynamics
of breast cancer PDX models and found that in each of the 15
matched tissues examined, clonal diversity was reduced in the
PDX. Similar findings have been presented by Schutte et al.
(2017) for colorectal tumors and derived models, where the
latter reflected only a subset of consensus groups. Reasons for
these findings may be manifold, ranging from engraftment bias
to minor clones restricted to only small areas in the sample of
origin. Remarkably, similar clonal dynamics were observed in
matched xenografts and PD3D cultures established from the
same sample (Schutte et al., 2017). These examples suggest that
micro-environmental, stromal, and immune compartments on
one hand and deterministic mechanisms on the other underlie
the clonal selection found on engraftment. In conclusion,
PDX models partially recapitulate the complexity of clonal
dynamics observed in human cancers. Biases caused by the
engraftment can act as non-stochastic selection events, which
can specifically define a patient-derived model more than
limit it.
Clonal evolution is a complex process. During therapeutic
intervention, selective pressure may substantially alter a
heterogeneous composition. This may result in the need
for multiple-site repeated biopsies to decipher the clonal
composition in different regions of the tumor for evidence-
driven support of clinical decisions. This procedure would be
highly invasive, technically not applicable and prevented by
the current standard pathology routine. With this in mind,
PD3D models in combination with liquid biopsies (Aparicio
and Caldas, 2013; Murtaza et al., 2013) may prove useful. In
addition to manifested genomic aberrations, aberrant DNA
methylation patterns in cancer can blur the lines between
distinct phenotypic “attractor states” or “cancer stem cells”
(Marusyk et al., 2012), making them drivers of malignant
progression independent of their genetic background. To
track isogenic cellular clones in various cancer PDX models,
including colorectal cancer, lentiviral tagging has been used to
barcode individual cells and their progeny. It has been found
that relatively rare quiescent sub-clones (putative cancer stem
cells) in colorectal PDXs are able to recapitulate the entire
tumor bulk heterogeneity after treatment with chemotherapy
(Kreso et al., 2013; Nguyen et al., 2014). Moreover, it has been
shown that the genetic background of these quiescent cell
populations is similar to their highly proliferative counterparts.
In a follow-up publication, they were linked to the stem cell
BMI1+ population present in the intestinal and colonic crypts
(Kreso et al., 2014). By definition, these cellular clones were
isogenic, so it can be speculated that microenvironmental
factors may have regulated cellular plasticity by supporting
distinct gene expression patterns or epigenetic attractor states
(Michor and Weaver, 2014). Hence, the microenvironment’s
composition in a PDX could profoundly alter the phenotype of
donor cells, rendering drug sensitivity experiments difficult to
interpret.
Matrigel is often used as a scaffold to increase engraftment
efficiency in PDX models; however, for more representative
results, this murine basement membrane extract is usually
replaced by suitable synthetic alternatives, which have a defined
presence of growth factors, structure, and protein composition,
mimicking tissue-specific ECM, where needed (Cassidy, 2014). It
has been shown that following tumor tissue xenotransplantation,
murine stromal cells progressively replace corresponding human
cells. Despite some differences between the ligand repertoires
of donor and host fibroblasts, both types of fibroblasts are able
to interact with cancer cells (Argent et al., 2010). How this
partial compatibility reflects the patient’s stroma with regard
to stroma composition and its influence on tumor growth and
development remains elusive. To reduce the influence of murine
stroma on the PDX model, many have begun to explore
co-engraftment of human mesenchymal stem cells (MSC) or
CAF cell lines in PDXs. Resistance to cytotoxic therapies among
these cell lines is variable, and it is controlled by the intracellular
hepatocyte growth factor (HGF)/c-Met signaling (Argent et al.,
2010; Straussman et al., 2012). One promising approach is
the direct isolation of patient-derived fibroblasts and the
co-engraftment of these matched stromal components. This
would significantly increase the advantages these models already
have in retaining the complex heterogeneity found in patient
samples.
The most obvious bias of using PDX models to study
human tumor progression is the lack of an immune component
in mice. The consequence of genetic alterations accumulated
during tumor evolution is also strictly linked to the propagation
of a large repertoire of neoantigens. The main focus of
immunotherapy is to target these neoantigens. In the most
straightforward approach, significant CD8+ cytotoxic T-cell
infiltration would lead to tumor cell death. However, during
progression, most tumors eventually evade the immune system.
For that reason, co-engraftment of immune components into
PDX models could help basic research to better understand
patient-specific crosstalk of tumor progression and immune
surveillance at different stages of the disease and furthermore
help in the designing of novel therapies targeting tumor–immune
interactions. The co-engraftment of human bone marrow stem
cells with liver and thymus tissues provides a solid method
to reconstitute the human immune system in immunodeficient
mice (Shultz et al., 2007). However, the complexity needed to
generate this modelmakes it largely unfeasible in clinical settings.
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On the other hand, the use of transplanted CD34+ hematopoietic
stem cells in immunocompromised mice seems to be a suitable
and feasible system to generate patient-matched humanized PDX
(huPDX).
CONCLUSION AND PERSPECTIVE
As our knowledge on cancer development and disease
progression grows, the demand for reliable models increases.
Simple modeling of pathway activation using monoclonal
adherent cell lines is no longer sufficient when it comes to
predicting therapeutic responses in 3D tissue. Within the
tumor, cooperation and competition between genetically and
phenotypically distinct sub-clonal populations seem to drive
tumor growth, resistance to therapy, and recurrence. Today,
an entire toolbox of preclinical in vitro, in vivo, and in silico
models is available to unscramble the complexity of ITH. All
of these models have utility in basic cancer research and to
a certain degree have demonstrated clinical predictive power.
PD3D models can be reliably generated directly from the
tumor tissue of either a primary or a metastatic lesion. The
high degree of flexibility of PD3D cell cultures resides in their
self-organizing nature; in their easy molecular manipulation,
including CRISPR-mediated gene editing; and in their suitability
for high-throughput drug screening. Moreover, PD3D cell
culture models are able to maintain both the functional cell
hierarchy and the polyclonal architecture of tumor biopsies, and
when derived by multi-regional sampling at different time points,
they can represent a reliable model to study tumor evolution in
time and space, resulting in a deeper understanding of how to
exploit these mechanisms for therapeutic intervention in clinical
scenarios. Nevertheless, the development of more complex
PD3D cell culture models, including cellular components of the
microenvironment to mimic in vitro the interplay of immune and
other stromal cells with the tumor in response to therapies, would
be necessary to increase the predictive value of such models.
Moreover, in our opinion, major efforts are needed to correlate
the abilities of PD3D cell cultures with reliable drug responses
observed in cancer patients, with the aim of integrating such data
into the clinical decision-making process where possible.
Advancements in xenograft models, such as co-culture models
of human tumors with human stroma and/or immune cells, make
PDX models an ideal extension for in vitro experiments. These
co-models recapitulate the complexity of human malignancy
remarkably well with regard to the interaction with stromal
or immune components. Nevertheless, as our understanding
of graft vs. host interactions remains limited, data from these
models must be interpreted with care. With the advent of systems
biology, all existing data on clonal evolution in patients and
matched in vitro and in vivo will be used to train algorithms to
better model treatment response. In consequence, the coalescence
of these approaches will bring a better understanding of
the evolution of tumors and of their interaction with the
(micro)environment. In the future, more proactive models of
intra-tumor heterogeneity for drug development and treatment
strategies will emerge.
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